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During IgE-mediated events, basophils secrete small 
molecular weight mediators (histamine, slow reacting 
substance, Eosinophil chemotactic factor) which are 
thought to participate in inflammatory processes. We 
here describe the lgE-mediated secretion of large molec-
ular weight mediators which have the potential for the 
activation of the Hageman factor dependent pathways, 
and the generation of biologically active peptides. These 
large molecular weight basophil derived mediators may, 
through the activation of the Hageman factor dependent 
pathways, influence mechanisms which participate in 
both acute and chronic cell-mediated inflammatory proc-
esses. 
We suggest that these proteases may participate not 
only as mediators of the immediate hypersensitivity re-
action, but may also function in important aspects of the 
entire inflammatory response. 
Human peripheral leukocyte preparations from allergic do-
nors, when challenged with the appropriate antigens, release 
several chemical mediators including histamine, slow reacting 
substance (SRS), and eosinophil chemotactic factors [1]. The 
release processes which are involved have been extensively 
described. In each instance, the mediators are actively secreted 
by a process which is temperature and calcium-dependent, 
require metabolic energy, and is controlled by hormone-recep-
tor interactions which influence the intracellular level of cyclic 
nucleotides [2,3]. While much attention has been given to the 
possible role of these small molecular weight mediators in 
inflammatory or allergic reactions, little data has been available 
pertaining to the possible role of high molecular weight media-
tors which are also actively secreted during the IgE-mediated 
response. Recent studies of mast cell systems have revealed 
that, during secretory 'events, large molecular weight complexes 
may be secreted which possess biologically active molecules. 
Thus, heparin, bound to a large molecular weight proteoglycan, 
is secreted and is biologically active [ 4]. Our work, in the 
basophil system, also suggests that biologically active molecules 
are secreted bound to large molecular weight complexes (pos-
sibly fragments of granular matrices). We have described a high 
molecular weight complex which has at least 3 activities asso-
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cia ted with it: a tosyl arginine methyl ester (TAMe) esterase 
activity, a kinin-cleaving protease, and a Hageman factor cleav-
ing protease [5-9]. In this discussion, we will address ourselves 
primarily to the newly described large molecular weight media-
tors which we have termed "basophil kallikrein-like activities" 
(BK-A) and only briefly review new information regarding the 
small molecular weight mediators. 
Experimental Studies of the Basophil Kallikrein-like 
Activities 
When basophil preparations are challenged with either pu-
rified protein antigens, such as ragweed antigen E, or with 
highly specific anti-lgE, they release a TAMe esterase activity. 
Our studies on the mechanism of the release of BK-A have 
primarily concentrated on this esterase activity since its mea-
surement is relatively easy and precise. As will be indicated 
below, however, it cannot be assumed that TAMe esterase 
activity parallels each of the biological activities of BK-A. 
A typical dose-response curve for the release ofT AMe ester-
ase is shown in Fig lA. In general, the pattern of histamine and 
TAMe esterase release is similar, whether the release is initiated 
by antigen or by anti-IgE. The maximal percentage of histamine 
or TAMe esterase release has, however, no fixed relationship. 
This differential release of histamine and TAMe esterase is 
similar to the observations of others relating to differential 
release of enzymes from the neutrophil [10]. In this cell type, 
which shares a common cell of origin with the basophil, the 
release of beta-glucuronidase from the azurophil granule and 
lysosyme from the specific granule are often quite different. 
There have also been reports showing differential release of 
histamine and SRS-A from mast cells [11]. 
While the quantity of histamine and TAMe esterase release 
may differ, the rate of release of the 2 mediators shows no 
significant difference (Fig lB). Similarly, release of both hista-
mine and TAMe esterase is temperature and calcium-depen-
dent. Not only is the initiation of release of TAMe esterase 
temperature sensitive but decreasing the temperature at any 
time during the release process stops the reaction abruptly. The 
release . is also absolutely dependent upon the extracellular 
calcium concentration and the addition of EDT A at any time 
during the process causes a similar rapid cessation of release 
[7]. 
Modulation ofT AMe esterase release has been studied using 
the same series of agonists utilized to explore the control of 
histamine release. Agonists which act on specific receptors to 
activate adenylate cyclase inhibit the 2 processes similarly. For 
example, Fig 2A shows that prostaglandin E1 inhibits both 
processes in a dose-dependent fashion. Similar experiments 
have been carried out with beta-adrenergic agonists, histamine, 
and cholera enterotoxin. In each case, the inhibition dose-
response curves were essentially identical. Agents, such as 
theophylline, which act by inhibiting the cAMP phosphodies-
terase inhibit the release of histamine and of esterase with a 
similar pattern (Fig 2B) . Cochicine, which causes disaggregation 
of microtubules, is a potent inhibitor of histamine release while 
heavy water (D20), which favors microtubular aggregation, is 
a potent enhancer of this process. Together, the 2 agents are 
antagonistic, so that their effects cancel. Similar studies with 
respect to esterase release showed that cochicine inhibited the 
process while D 20 caused a potentiation of release [7]. The 
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need for metabolic processes in the release of TAMe esterase 
was studied with 2-deoxyglucose, an inhibitor of glucose phos-
phorylation. These studies revealed that the TAMe esterase 
release is entirely energy-dependent. The concentration of 2-
deoxyglucose required for 50% inhibition of release is similar 
for the TAMe esterase (0.4 mM) and histamine release (0.3 mM) 
[7]. 
After demonstrating that the release process and the phar-
macologic control of esterase release was similar to that of the 
previously described mediators, we next attempted to purify 
the esterase and to ascertain its relationship to the biological 
activities (cleavage of kininogen to produce immunoreactive 
kinin and cleavage of Hageman factor) which had been observed 
in the crude supernatants. For this purpose, large quantities of 
the basophil supernatant were obtained by challenge of leuko-
cyte preparations with anti-lgE or antigen E and these super-
natants were sequentially cluomatographed . on Sephadex G-
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FIG l. a, Dose-response of Rye Group I antigen induced release of 
a basophil TAMe esterase. b, Kinetics of AgE-induced (17 ng/ ml) 
histamine and TAMe esterase release from basophils. 
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FIG 2. Inhibitory effects ofPGE 1 (Fig 2A) and theophylline (Fig 2B) 
on TAMe esterase and histamine release from basophils. For each drug, 
the molar concentrations required for 50% inhibition of release are 
similar for histamine and the TAMe esterase. 
200, DEAE-Sephacel and Sepharose 6B. The chromatography 
on Sephadex G-200 yielded only one TAMe esterase-active 
peak, which was eluted in the void volume. When this was 
chromatographed on DEAE-Sephacel and eluted with a linear 
salt gradient, a Single peak of esterase activity was again ob-
tained. However, chromatography of this peak on Sepharose 
6B led to a more complex pattern (Fig 3). A major peak of 
esterase activity was observed which coincided with the first 
absorption peak and eluted with an estin1ated molecular weight 
of 1.2 million. A second esterase peak was present, but was 
quantitatively of smaller magnitude and smaller molecular 
weight (c. 400,000). A third arginine esterase peak was variably 
present and was quantitatively of even smailer magnitude than 
the 2 other forms . This third form also had the smallest molec-
ular weight, approximately 70,000. 
These fractions were then examined for their ability to gen-
erate immunoreactive kinin and to cleave Hageman factor. 
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FIG 4. Arginine esterase activity and kinin generation by anti-lgE 
generated supernate ch.romatographed on Sepharose 6B (cpm x 10- ') . 
Figure 4 shows the relationship between TAMe esterase activity 
and the generation of immunoreactive kinin from the first, high 
molecular weight peak of the Sepharose 6B column. It is evident 
that the 2 activities co-chromatograph. This assay was carried 
out with acid treated, heat inactivated plasma. More recently, 
it has been shown that the same protease can cleave purified, 
high molecular weight kininogen to yield immunoreactive kinin 
[6-7]. 
Similar studies have not been completed with respect to th~ 
mediator which cleaves Hageman factor. It is clear, however, 
that while there is TAMe esterase activity associated with the 
first 2 peaks, there is little present in the last, small molecular 
weight peak; fractions from the last peak were, however, most 
potent in cleaving Hageman factor. 
The activity of the basophil Hageman factor (HF) protease 
is shown in Fig 5. Radiolabeled Hageman factor was adsorbed 
to a glass surface after which it was cleaved by either plasma 
kallikrein or the basophil HF protease. After cleavage, samples 
were analyzed by electrophoresis on SDS-PAGE as previously 
described [9,12]. The top panel shows intact Hageman factor, 
with a molecular weight of 80,000. The middle panel shows the 
cleavage of Hageman factor by purified human plasma kalli-
krein. Part of the radiolabeled Hageman factor remains intact 
while the rest is cleaved into fragments of approximately 28,000 
and 52,000 daltons. The lower panel shows cleavage of Hageman 
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factor by the basophil HF protease. As with plasma kallikrein, 
part of the radiolabeled Hageman factor remains uncleaved 
while the rest is split into fragments of 28,000 and 52,000 
daltons. Additional studies have determined that the 28,000 
molecular weight fragment produced by the basophil enzyme 
has functional activity as assessed by its ability to activate 
prekalliluein to kallikrein [9].-
Studies with Other Mediators 
Perhaps the most interesting recent observation with respect 
to several of the mediators has to do with the role of arachidonic 
acid (AA) metabolism in the release process. With respect to 
histamine release, it has been shown that ETYA, which blocks 
both the lipoxygenase and cyclo-oxygenase pathways of AA 
metabolism, completely inhibits the release of histamine. On 
the other hand, the nonsteroidal anti-inflammatory drugs 
(NSAID) such as indomethacin, aspirin and meclofenamic acid, 
which are selective inhibitors of the cyclo-oxygenase pathway 
of arachidonic acid metabolism, potentiate the release of his-
tamine. These observations suggest that a product of the lipox-
ygenase pathway is necessary for histamine release and that 
the NSAID act by shifting arachidonic acid metabolism to that 
pathway. In keeping with this suggestion was the fact that 
arachidonic acid itself also potentiated histamine release [13]. 
A related observation was that indomethacin and other NSAID 
selectively block the inhibition of histamine release caused by 
each of the agonists (isoproterenol, histamine, adenosine, pros-
taglandins) which act through specific receptors to increase 
adenylate cyclase activity. Arachidonic acid has a similar activ-
ity. In contrast, neither indomethacin nor arachidonic acid had 
any effect on the inhibition of release caused by drugs or agents 
which increase cyclic AMP by other mechanisms. Thus, they 
did not reverse the inhibition caused by theophylline or isobu-
tylmethylxanthine which are phosphodiesterase inhibitors; sim-
ilarly, they had little or no effect on the inhibition caused by 
dibutyryl cyclic AMP itself [13]. These data strongly suggest 
that there must be subcompartments of cyclic AMP which are 
differently affected by cyclase agonists and by other agents 
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FIG 5. Cleavage of human Hageman Factor by preparations of the 
basophil HF protease. 
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which increase cyclic AMP. It further suggests that not only is 
there a product of the lipoxygenase pathway necessary for 
histamine release but that another (or the same) product of 
that pathway modulates the effects of endogenous hormones or 
pharmacologic agents on the control of histamine release. 
Also related to arachidonic acid m etabolism is the recently 
described structure of slow reacting substance (SRS) . Samuel-
son et al have demonstrated that SRS is derived from the 
lipoxygenase pathway of arachidonic acid metabolism, with an 
additional step which incorporates cysteine into the molecule 
to yield what has been designated leukotriene C [14]. The 
precise role of SRS in inflammatory conditions is not fully 
elucidated but, with respect to smooth muscle, the duration of 
its action is known to be much longer than that of histamine. 
The definition of the structure of SRS should, for the first time, 
allow the synthesis of a series of antagonists which can delineate 
the role of this mediator in inflammatory processes. 
Another interesting observation is that the major source of 
SRS in inflammatory reactions is probably not basophils or 
mast cells, but other cell types. This has been described by 
Bach in rat peritoneal cells [15] and we have demonstrated that 
SRS is readily derived from human polymorphonuclear leuko-
cytes [16]. 
There are a number of eosinophil chemotactic factors (ECF) 
produced from mast cells and basophils. Two of these have 
been characterized as tetrapeptides by Goetz! and Austen 
[17]. However, here, as well, there is the recent observation 
that eosinophil chemotactic factors can be readily obtained 
from polymorphonuclear leukocytes by challenge with calcium 
ionophore or as a result of a phagocytic stimulus. There is 
further evidence that arachidonic acid is either the precursor of 
the neutrophil ECF or enhances its production (18]. Platelet 
activating factor (P AF) has been described in rabbits as a 
basophil mediator which causes the secretion of serotonin from 
platelets. In primate species, however, this lipid mediator also 
appears to be derived primarily from nonmast cells or basophil 
sources [19]. 
It is possible to generalize, then, that the nonpreformed lipid 
mediators (SRS, ECF, PAF) which have previously been asso-
ciated wit h IgE-mediated reactions in mast cells or basophils 
exist in and are commonly released from other cell types. It is 
likely that these mediators are generated as a result of the 
increase in phospholipid metabolism which occurs in activated 
cells, not only during the allergic response, but in other cell 
types activated by appropriate stimuli. 
DISCUSSION 
We h ave tried to point out that, in addition to the small 
molecular weight mediators of inflammatory reactions, there is 
a series of high molecular weight mediators which are released 
from basophils following interaction of antigen and IgE ant i-
body. These mediators have the ability to generate kinin from 
human plasma kininogen and to activate human Hageman 
factor. The importance of these mediators is illustrated in Fig 
6. Thus, BK-A, by acting on Hageman factor, is capable of 
yielding the biologically active 28,000 molecular weight frag-
ment B-HFn which is capable of activating prekallikrein to 
kallikrein, which can either cleave plasminogen to produce 
plasmin or act on kininogen to generate kinin. Each of these 
activation steps is subject to control so that BK-A's additional 
ability to generate in1munoreactive kinin from kininogen is an 
important "feed forward" aspect of these reactions. These are 
the first mediators from basophils (though similar mediators 
are released through IgE-mediated mechanisms in the m ast cell 
[20] which are capable of interacting with the coagulation and 
kallikrein-kinin systems to genemte biologically relevant pep-
tides. In fact, this represents the only known immunologic 
pathway into these plasma cascade systems. 
We have previously suggested that certain of the chemical 
mediators, such as histamine, pal'ticipate not only in immediate-
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FIG 6. Activation of th e Hageman factor dependent pathways of 
coagulation , fibrinolysis and kinin formation by a basophil HF protease. 
type inflammatOl'y l'eactions but also function in important 
aspects of the entire inflammatory process. While the role of 
the basophil kallikrein-like activities in immediate h ypersensi-
tivity reactions and in other inflammatory processes is not 
clear, they do represent a first and important interface between 
IgE-mediated reactions and t he Hageman factor dependent 
pathways of t he inflammatory response. By virtue of th ese 
activities, the basophil kallikrein-like activities may influence 
mechanisms which are involved in both subacute and chronic 
cell-mediated inflammatory processes. ' 
T~ere has been_ rece~t interest in the involvement of IgE-
medJated mechamsms m delayed reactions and in cutaneous 
basophil hypersensitivity, both of which represent subacute or 
chronic phases of inflammation. Dvorak and his associates have 
sh own t hat, in these types of reactions, there is activation of 
t he coagulation system [21]. Perhaps, during an IgE-mediated 
skin reaction, basophils and m ast cells secrete the above-de-
scribed pro teases which activate the Hageman factor dependent 
pathways, thus resulting in the inflammatory pr ocesses which 
are observed dming delayed skin reactions. Studies by Dvorak 
a_nd_ hi~ associates and by Askenase also show the deposition of 
f1bnn m and around inflammatory lesions associated with cu-
taneous basophil hypersensitivity [22-23]. It is possible that the 
basoph.ils, through the m echanisms described above activate th~ _coagulatio~ ~ystem a~d ~re responsible for the fi'brin dep-
ositiOn. In add1t10n to bemg mvolved in subacu te and chronic 
inflamma_tory reactions, the mediators described here may be 
mvolved 1~ more acute r_eactions. Thus, we have reported the 
consumpt1~n of coagulatiOn factors dming human anaphylaxis 
[24] and Pmckard and his associates have observed the same 
phenon:e~on in_systemic anaphylaxis in rabbits [25]. There has 
? een chmcal e~1dence that there ar e coagulation abnormalities 
m anap~ylact1c r~actions and BK-A may well provide the 
mechamsm by which this occurs. 
. ~he basic _bioch emistry of the coagulation system and the 
km~n gene~·atmg system has been appreciated for a considerable 
penod of tune. How this is activated in vivo has not been clear 
particularly from an immunologic point of view and the media~ 
tor~ we have d~scribed represent the first link between antigen 
actiVated reactwns and the plasma cascade systems. 
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DISCUSSION 
STREILEIN: Do you know anything about the differential 
release of BKA versus histamine? 
LICHTENSTEIN: Yes, histamine and the esterase have the 
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same dose response relationships and the same kinetics, but the 
absolute amounts which are released are quite different. It is 
almost as if there are 2 separate granules, one of which releases 
histamine and one of which releases this other mediator. 
WuEPPER: Which of the 2 kininogens is the substrate for 
BKA? 
LICHTENSTEIN: It has been demonstrated to cleave the high 
molecular weight kininogen; recently Kaplan said that it may 
also cleave the low molecular weight kininogen. 
WUEPPER: Can you reduce that very high molecular weight 
material in any manner? 
LICHTENSTEIN: I did point out that the chromatogram has 2 
forms of the enzyme at 400,000 and 70,000 molecular weight; 
both have esterase activity. I think it's becoming clear now that 
the material which activates Hageman factor is not necessarily 
the same as that material which has kallikrein activity, but this 
is work in progress. 
WUEPPER: Is the material performed in granule? 
LICHTENSTEIN: The esterase is performed. 
GIGLI: If you add the purified esterase to normal human 
serum, do you see any of the changes in serum proteins seen in 
the patient whom you described? 
LICHTENSTEIN: Our work has been primarily involved in 
trying to purify the various activities. I do know whether 
addition of some of the peaks to plasma produces coagulation 
abnormalities, but they certainly have not been studied in any 
defined fashion. 
MANNIK: Do you think the interaction of IgE molecules with 
receptor and the release phenomena are related primarily due 
to conformational changes of the antibody molecule vs. poly-
valency of the ligands? Have association constants been com-
pared between monomeric ligands and di- or polyvalent ligands? 
Finally, how does the Fe fragment of IgE interact with the 
receptors on mast cells? 
LICHTENSTEIN: Terry Ishizaka has made an anti.receptor 
antibody to rat mast cells and found that you do not need IgE 
to induce histamine release. All you have to do is bring 2 
receptors together, so I think that IgE is, in a sense, irrelevant. 
MANNIK: Then how do you explain the differences that you 
noted in terms of the inhibitors intelferi.ng differently, if you 
used an antigen vs. aggregates of IgE? 
LICHTENSTEIN: With BP02, you get a very symmetrical dose 
response curve. It goes up, peaks, and returns to base line; you 
can relate the release mathematically to the number of IgE 
cross links. Anti IgE does almost the same thing. There are 
reasons to believe that anti-IgE stimulates release by cross-
linking on 2 IgE molecules. Antigens almost surely form more 
complex interactions with the IgE. You can visualize clumps of 
a ntigel)-antibody complexes on the cell sw-face. I believe that 
it is this which constitutes the different stimulus. 
DvoRAK: Do human basophils release proteases other than 
kallikrein during antigen induced degranulation? 
LICHTENSTEIN: There are at least 2, and probably more 
activities coming out. 
CLAMAN: I did not understand a point about the free recep-
tors for lgE. If, indeed, the affinity of the receptors for IgE is so 
high, what determines what cells will have receptors for lgE 
which are occupied. 
LICHTENSTEIN: It follows form very simple physical chemis-
try . If you measw-e the affinity of the lgE receptors for IgE in 
different individuals; they vary over about a 30-fold range, so 
that there is some diversity of receptor affinity . The only times 
that there are free receptors is there are low (20-30 ng/ ml) 
concentrations of serum lgE. If you look at the equilibrium 
constant and the concentration of IgE you get as much satu-
ration as you would expect. 
